Compass Therapeutics shares are plummeting due to a significant FDA setback for their key drug, tovecimig. The requirement for a survival benefit trial before BLA submission introduces substantial delays and increased costs, casting doubt on the drug's future and the company's valuation.
This headline represents a major negative catalyst for Compass Therapeutics. The FDA's recommendation for a survival benefit trial is a significant hurdle, indicating that the current data is insufficient for BLA submission. This will lead to substantial delays in potential market entry for tovecimig, increased R&D costs, and a higher risk of the drug never reaching the market. Investors are reacting to the prolonged timeline and increased uncertainty, leading to a sharp decline in share price. This event highlights the inherent risks in the biotechnology sector, particularly for companies with a limited pipeline heavily reliant on a single drug candidate.